* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Click here to download
		                    
		                    
								Survey							
                            
		                
		                
                            
                            
								Document related concepts							
                        
                        
                    
						
						
							Transcript						
					
					Medication Management of the Chronic Pain Patient Benjamin Meeks, CFNP Pain Medicine Associates Overview  Overview of Pain Transmission  Rational Poly-pharmacy  NASIDS  Antidepressants  Anti-Seizure Medications  Topical Medications  Opiates  Cannabinoids Transmission of Pain  Peripheral Sensitization  Peripheral Neurons  Ascending Spinal Cord  Brain Structures/Mechanisms  Descending Spinal Cord Peripheral Sensatization  Painful Stimuli  Sodium and Calcium Channel Depolarization  Glutamate  Substance P  Bradykinin  Prostaglandin  Tumor Necrosis Factor Alpha  Glial Cells, Schwann Cells, Microglia, Astrocytes  Nitric Oxide  Arachidonic Acid Ascending Spinal Cord  Dorsal Horn  NMDA, AMPA G-Protein and Tyrosine Receptors  Summation Response  Spinothalamic Tract Brain  Singnal from Spinothalamic Tract  Concioius perception of pain  Serotonin/Norepinephrine  Endogenous Opioids in Periaqueductal Gray Descending Spinal Cord  Norepinephrine (Inhibitory)  Serotonin (Inhibitory and Excitatory)  Dopamine (Inhibitory and Excitatory) Rational Poly-Pharmacy  Norepinephrine  Opiate Receptors – Peripheral and Central Afferents  Peripheral Sensitization  COX-2/Acid Sensitive Channels  Subsbstance P  Calium and Sodium Channels  Prostaglandins “Multidrug analgesic approaches take advantage of complementary mechainisms of different drug classes to enhance analgesia” NSAIDS  Inhibit Cyclooxygenase, prostaghaldins and acid-sensative ion channels  GI, Kidney Risk, Coronary Risk  Opiate Sparring Antidepressants  TCA's  Norepinephrine,Imipramine, Amitryptiline, Desipramine  Anticholinergic Side Effects  Cariovascular Toxicity  SSRI's – Little data to support use in pain  Venlafaxine – Pain data is mixed  Milnacipran – Norepinephrine Reuptake Inhibitor   FDA approved fibromyalgia Duloxetine  Inhibit serotonin and norephephrine uptake  FDA approved for diabetic peripheral neuropathy, low Antiseizure Medications  Stabilize Calcium and/or Sodium Channels  Increases Spinal Norepinephrine Concentration    Carbamaepine, Oxycarbamazepine, Gabapentin, Pregabalin, Topiramate, Lamotragine Extensively studied in peripheral neuropathic states Dizzyness, somnolence and peripheral edema Topical Medications  Capsaicin – Substance P depletion   Lidocaine – Sodium Channel Blockade    OTC Ointment – prescription patch 3 – 10% Ointment or 5% patch Compounded Ointments/Gels  Lidocaine, Baclofen, Ketoprofen, Amitrytyline, Gabapentin, Ketamine, Cyclobenzaprine  Opioids – No controlled studies Topical Diclofenac  Gel or patch  Better tolerated than by mouth Opiates  Immediate Release  Extended Release Immediate Release Opiates  May be associated with increased risk of tolerance and addiction compared to extended release opiates  Analgesic Half-life 2 – 4 hours  Onset by mouth 5 – 40 minutes  Oxycodone, oxymorphone, codeine, morphine, hydrocodone, hydromorphone, tramadol, tapentadol  Constipation, nausea, confusion, dizzyness, itching  Indicated for as needed usage Immediate Release Opiates   Buprenorphine – Mu agonist/antagonist long half life suitable for once daily dosing Methadone – Mu/NMDA agonist  Unpredictable half-life Extended Release Opiates    May be associated with low risk of tolerance and addiction Indicated to chronic pain in patients who require constant opiate dosing MS ER tabs, MS ER Capsules, Hyromorphone ER Tabs, Oxycodone ER Tabs, Oxymorphone ER Tabs, Tramadol ER tabs, Tapentadol ER Tabs, Fentanyl Patch, Buprenorphine Patch Cannabinoids   Dronabinol FDA approved for chemotherapy induced nausea and AIDS wasting Smoked and Nebulized Cannabinoids activity at Mu and Delta receptors  Does not alter opiate pharmacokinectics  Little placebo controlled data for chronic pain  Low dose nebulized canabinoid not assoctied with “high” Summary Cyclooxgenase Calcium/Sodium Channels Norephrine Re-Uptake Mu-Agonists NSAIDS Gabapentin Nortriptyline Codeine Diclofenac Patch Carbamazepine Amitryptline Hydrocodone Dicofenac Gel Oxcarbamazepine Desipramine Hydromorphone Compound Gels Pregabalin Imipramine Tramadol Zonisamide Tramadol Tapentadol Lamotrgine Tapentadol Morphine Topical Lidocaine Duloxetine Oxycodone Savella Oxymorphone Methadone Fentanyl Buprenorphine Questions? Questions?
 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
                                             
                                             
                                             
                                             
                                             
                                             
                                             
                                             
                                             
                                             
                                            